Overview
Find detailed information on selected clinical trials for Osteosarcoma at Cincinnati Children's Hospital Medical Center.
There are two versions of some of the trials. While they contain the same basic information, one version is geared toward healthcare professionals and the other is geared toward families.
| Trials | Healthcare Professional Versions | Family-Friendly Versions |
|---|
| ADVL0612: A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children with Refractory Solid Tumors | Professional | Family-Friendly |
| NCI-07-C-0040: A Phase I Trial of the Monoclonal Antibody HGS-ETR2 (Lexatumumab) in Patients with Refractory Pediatric Solid Tumors | Professional | Family-Friendly |
| ADVL0413: Phase I Study of the RAF Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children with Refractory Solid Tumors or Refractory Leukemias | Professional | Family-Friendly |
| ADVL0525: A Phase II Study of Pemetrexed Disodium in Young Patients With Relapsed or Refractory Solid Tumors | Professional | |
| AOST0331: A Phase III Randomized Study of Neoadjuvant Induction Therapy Comprising Doxorubicin, Cisplatin, and High-Dose Methotrexate (MAP) Followed by Surgery and Adjuvant Maintenance Therapy Comprising MAP Alone Versus MAP and PEG-Interferon Alfa-2b OR MAP Combined With Ifosfamide and Etoposide in Patients With Resectable High-Grade Osteosarcoma | Professional | |
